Bohdan Bybel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bohdan Bybel has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- William Donald Leslie
Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
2 shared publications Donald R. Neumann
1 shared publicationFrank P. DiFilippo
1 shared publicationGuiyun Wu
1 shared publicationI. David Greenberg
From the *Section of Nuclear Medicine, Health Sciences Centre, Winnipeg, Manitoba, Canada; and †Section of Nuclear Medicine, St. Boniface Hospital, Winnipeg, Manitoba, Canada
1 shared publicationJaylene Rtnm Ducharme
From the *Section of Nuclear Medicine, Health Sciences Centre, Winnipeg, Manitoba, Canada; and †Section of Nuclear Medicine, St. Boniface Hospital, Winnipeg, Manitoba, Canada
1 shared publication
Latest Publications
- 1 June 2011
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 36 (6) , 452-456
Increased F-18 FDG Intestinal Uptake in Diabetic Patients on Metformin
Purpose: A matched case–control study was performed to assess the relationship between metformin use and the degree of F-18 fluorodeoxyglucose (FDG) bowel activity in diabetic patients. Materials and Methods: Seventy-seven diabetic patients referred to our department for a positron emission tomography/computed tomography study, including 45 on metformin, were compared with nondiabetic controls matched for sex, age, and body mass index. Positron emission tomography studies were obtained in a standard manner and reviewed in a blinded fashion. F-18 FDG uptake in the GI tract was evaluated quantitatively using maximal standardized uptake values and visually using a previously published semiquantitative scale. Results: F-18 FDG uptake in small and large bowel was significantly increased in metformin patients compared with nondiabetic controls both visually and quantitatively (all P < 0.0001), as well as compared with nonmetformin patients with diabetes. Control sites (liver, fat, muscle) showed similar uptake. Multiple regression analysis confirmed that metformin was the variable most strongly associated with bowel uptake. Conclusion: Physiologic accumulation of F-18 FDG in bowel is increased in diabetic patients maintained on metformin.
- 1 June 2011
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 36 (6) , 452-456
Increased F-18 FDG Intestinal Uptake in Diabetic Patients on Metformin
Purpose: A matched case–control study was performed to assess the relationship between metformin use and the degree of F-18 fluorodeoxyglucose (FDG) bowel activity in diabetic patients. Materials and Methods: Seventy-seven diabetic patients referred to our department for a positron emission tomography/computed tomography study, including 45 on metformin, were compared with nondiabetic controls matched for sex, age, and body mass index. Positron emission tomography studies were obtained in a standard manner and reviewed in a blinded fashion. F-18 FDG uptake in the GI tract was evaluated quantitatively using maximal standardized uptake values and visually using a previously published semiquantitative scale. Results: F-18 FDG uptake in small and large bowel was significantly increased in metformin patients compared with nondiabetic controls both visually and quantitatively (all P < 0.0001), as well as compared with nonmetformin patients with diabetes. Control sites (liver, fat, muscle) showed similar uptake. Multiple regression analysis confirmed that metformin was the variable most strongly associated with bowel uptake. Conclusion: Physiologic accumulation of F-18 FDG in bowel is increased in diabetic patients maintained on metformin.
- 1 December 2009
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 34 (12) , 918-919
Abnormal F-18 FDG Uptake in Two Epidermoid Cysts on PET/CT
- 1 December 2009
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 34 (12) , 918-919
Abnormal F-18 FDG Uptake in Two Epidermoid Cysts on PET/CT
- 1 July 2008
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 28 (4) , 1097-1113
SPECT/CT Imaging: Clinical Utility of an Emerging Technology
Single-photon emission computed tomography (SPECT) has been a mainstay of nuclear medicine practice for several decades. More recently, combining the functional imaging available with SPECT and the anatomic imaging of computed tomography (CT) has gained more acceptance and proved useful in many clinical situations. Most vendors now offer integrated SPECT/CT systems that can perform both functions on one gantry and provide fused functional and anatomic data in a single imaging session. In addition to allowing anatomic localization of nuclear imaging findings, SPECT/CT also enables accurate and rapid attenuation correction of SPECT studies. These attributes have proved useful in many cardiac, general nuclear medicine, oncologic, and neurologic applications in which the SPECT results alone were inconclusive. Optimal clinical use of this rapidly emerging imaging modality requires an understanding of the fundamental principles of SPECT/CT, including quality control issues as well as potential pitfalls and limitations. The long-term clinical and economic effects of this technology have yet to be established.
- 1 July 2008
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 28 (4) , 1097-1113
SPECT/CT Imaging: Clinical Utility of an Emerging Technology
Single-photon emission computed tomography (SPECT) has been a mainstay of nuclear medicine practice for several decades. More recently, combining the functional imaging available with SPECT and the anatomic imaging of computed tomography (CT) has gained more acceptance and proved useful in many clinical situations. Most vendors now offer integrated SPECT/CT systems that can perform both functions on one gantry and provide fused functional and anatomic data in a single imaging session. In addition to allowing anatomic localization of nuclear imaging findings, SPECT/CT also enables accurate and rapid attenuation correction of SPECT studies. These attributes have proved useful in many cardiac, general nuclear medicine, oncologic, and neurologic applications in which the SPECT results alone were inconclusive. Optimal clinical use of this rapidly emerging imaging modality requires an understanding of the fundamental principles of SPECT/CT, including quality control issues as well as potential pitfalls and limitations. The long-term clinical and economic effects of this technology have yet to be established.
- 1 September 2007
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 32 (9) , 741-742
F-18 FDG PET/CT Following Dental Extraction in a Patient With Head and Neck Cancer
A 48-year-old man with squamous-cell carcinoma of the left tonsillar fossa and cervical lymph node metastases was being staged before radiation and chemotherapy. The patient had periodontal disease, and extraction of 2 teeth was performed before therapy. A staging PET/CT was performed 1 week after extraction. This case demonstrates increased FDG uptake at the extraction sites, which could be potentially mistaken for metastatic lesions, especially without the fused PET/CT images.
- 1 September 2007
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 32 (9) , 741-742
F-18 FDG PET/CT Following Dental Extraction in a Patient With Head and Neck Cancer
A 48-year-old man with squamous-cell carcinoma of the left tonsillar fossa and cervical lymph node metastases was being staged before radiation and chemotherapy. The patient had periodontal disease, and extraction of 2 teeth was performed before therapy. A staging PET/CT was performed 1 week after extraction. This case demonstrates increased FDG uptake at the extraction sites, which could be potentially mistaken for metastatic lesions, especially without the fused PET/CT images.
- 1 September 2004
- Vol. 32 (3) , 164-5
The helmet sign: Physiologic radioactive accumulation after 131I therapy--a case report.
After 131I radioablative treatment, a 51-y-old woman underwent whole-body (131)I scanning, which revealed intense uptake along the periphery of the skull. The patient disclosed that she had not washed her hair because she had obtained a new hairstyle between the 131I treatment and the scan. The intense uptake along the periphery of the skull represented radioactive physiologic accumulation at the patient's scalp.
- 1 September 2004
- Vol. 32 (3) , 164-5
The helmet sign: Physiologic radioactive accumulation after 131I therapy--a case report.
After 131I radioablative treatment, a 51-y-old woman underwent whole-body (131)I scanning, which revealed intense uptake along the periphery of the skull. The patient disclosed that she had not washed her hair because she had obtained a new hairstyle between the 131I treatment and the scan. The intense uptake along the periphery of the skull represented radioactive physiologic accumulation at the patient's scalp.